<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013216</url>
  </required_header>
  <id_info>
    <org_study_id>J2177</org_study_id>
    <secondary_id>IRB00288752</secondary_id>
    <nct_id>NCT05013216</nct_id>
  </id_info>
  <brief_title>Mutant Kirsten Rat Sarcoma (KRAS) -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer</brief_title>
  <official_title>Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stand Up To Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide&#xD;
      vaccine with poly-ICLC adjuvant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing study drug-related toxicities</measure>
    <time_frame>24 months</time_frame>
    <description>Number of participants experiencing study drug-related adverse events Grade 3 or higher as defined by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fold change in interferon-producing mutant-KRAS-specific CD8 T cells</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Evaluated by the fold change in interferon-producing mutant-KRAS-specific cluster of differentiation 8 (CD8) T cells after vaccination at 13 weeks compared to pre-vaccination baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fold change in interferon-producing mutant-KRAS-specific CD4 T cells</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Evaluated by the fold change in interferon-producing mutant-KRAS-specific cluster of differentiation 4 (CD4) T cells after vaccination at 13 weeks compared to pre-vaccination baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal percentage of change of interferon (IFN-γ) producing mutant-KRAS-specific CD8 T cells</measure>
    <time_frame>Baseline and 4 years</time_frame>
    <description>Maximal percent change of IFN-g prod mutant KRAS specific CD8 T cells at any time after vaccination compared to the pre-vaccination baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal percentage of change of IFN-γ-producing mutant-KRAS-specific CD4 T cells</measure>
    <time_frame>Baseline and 4 years</time_frame>
    <description>Maximal percent change of IFN-g prod mutant KRAS specific CD4 T cells at any time after vaccination compared to the pre-vaccination baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>High Risk Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>KRAS peptide vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRAS peptide vaccine</intervention_name>
    <description>KRAS peptide vaccine will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13.&#xD;
Drug: 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC</description>
    <arm_group_label>KRAS peptide vaccine</arm_group_label>
    <other_name>Hiltonol® (Poly-ICLC)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Must fall into one of the three categories defined as high risk of developing pancreatic&#xD;
        cancer:&#xD;
&#xD;
          -  High Risk Group 1 (familial pancreatic cancer relatives):&#xD;
&#xD;
               -  older than 55 years old or 10 years younger than the age of youngest relative&#xD;
                  with pancreatic cancer, and&#xD;
&#xD;
               -  Have 2 or more family members with a history of pancreatic cancer, and&#xD;
&#xD;
               -  Have a first-degree relationship with at least one of the relatives with&#xD;
                  pancreatic cancer.&#xD;
&#xD;
          -  High Risk Group 2 (Has gene mutation(s) with an associated with an estimated lifetime&#xD;
             risk of pancreatic cancer of approximately 10% or higher):&#xD;
&#xD;
               -  50 years old and has FAMMM (p16/CDKN2A) gene mutation.&#xD;
&#xD;
               -  older than 50 years old or 10 years younger than the age of the youngest relative&#xD;
                  with pancreatic cancer, and&#xD;
&#xD;
               -  Has known BRCA2, Acute Transverse Myelopathy (ATM), partner and localizer of&#xD;
                  BRCA2 (PALB2) gene mutation, and&#xD;
&#xD;
               -  There is more than 1 pancreatic cancer in the family, one of whom is a first- or&#xD;
                  second-degree relative of the subject to be screened.&#xD;
&#xD;
          -  High Risk Group 3 (Has gene mutation(s) with an associated with an estimated lifetime&#xD;
             risk of pancreatic cancer of approximately 5%):&#xD;
&#xD;
               -  Older than 55 years old or 10 years younger than the age of the youngest relative&#xD;
                  with pancreatic cancer, and&#xD;
&#xD;
               -  Has known BRCA1, or HNPCC (hereditary non-polyposis colorectal cancer or Lynch&#xD;
                  syndrome, hMLH1, hMSH2, postmeiotic segregation 1(PMS1), human MutS homolog 6&#xD;
                  (hMSH6), EpCAM) gene mutations, and&#xD;
&#xD;
               -  There is more than 1 pancreatic cancer in the family, one of whom is a first- or&#xD;
                  second-degree relative of the subject to be screened.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Patients must have adequate organ and marrow function defined by study-specified&#xD;
             laboratory tests prior to initial study drug.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
          -  Woman of childbearing potential must have a negative pregnancy test and follow&#xD;
             contraceptive guidelines as defined per protocol.&#xD;
&#xD;
          -  Men must use acceptable form of birth control while on study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If expected to require any other form of systemic or localized antineoplastic therapy&#xD;
             while on study.&#xD;
&#xD;
          -  Within 4 weeks prior to first dose of study drug.&#xD;
&#xD;
             o Any systemic or topical corticosteroids at immunosuppressive agents.&#xD;
&#xD;
          -  Within 4 weeks prior to first dose of study drug.&#xD;
&#xD;
               -  Any investigational device.&#xD;
&#xD;
               -  Has received a live vaccine.&#xD;
&#xD;
               -  Received any allergen hyposensitization therapy.&#xD;
&#xD;
               -  Any major surgery.&#xD;
&#xD;
          -  Infection with HIV or hepatitis B or C.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, uncontrolled&#xD;
             infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia,&#xD;
             metastatic cancer, or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements monoclonal antibody.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency.&#xD;
&#xD;
          -  Any other sound medical, psychiatric, and/or social reason as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Unwilling or unable to follow the study schedule for any reason.&#xD;
&#xD;
          -  Are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neeha Zaidi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Medical Institution</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trish Brothers, RN</last_name>
    <phone>410-614-3644</phone>
    <email>GIClinicalTrials@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joann Santmyer, RN</last_name>
    <phone>410-583-2970</phone>
    <email>GIClinicalTrials@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Trish Brothers, RN</last_name>
      <phone>410-614-3644</phone>
      <email>GIClinicalTrials@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joann Santmyer, RN</last_name>
      <phone>410-583-2970</phone>
      <email>GIClinicalTrials@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Neeha Zaidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KRAS Peptide Vaccine</keyword>
  <keyword>Neoantigen Vaccines</keyword>
  <keyword>Cancer Vaccines</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Pancreatic Ductal Adenocarcinoma (PDAC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

